Keratoconus is an eye disorder characterized by progressive thinning and changes in the shape of the cornea.
The initial Keratoconus treatment often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis, although generally, the results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line of treatment.
The current Keratoconus treatment option includes Intrastromal corneal ring segments (ICRS), Corneal reshaping and Cross-Linking (CXL) along with Riboflavin solutions + UV Light, Keratoplasty and Others (Antihistamine/mast cell–stabilizing topical medications, antihistamines, mast cell stabilizers, nonsteroidal anti-inflammatory (NSAID), which provide the corneal clinicians a variety of treatment options for the visual rehabilitation of Keratoconus patients. In the mild forms of Keratoconus , eyeglasses or soft contact lenses are preferred, however, their market has been excluded from the forecast model.
Keratoconus Market Insight
Keratoconus market size in 7MM in 2017 was USD 2,456 million
- Emergence of New Diagnostic Techniques
- Increasing Awareness of KC
- Genetic Factors
- Environmental Factors
Keratoconus Market Barriers
- Fewer patients available for clinical trials
- Lack of variety in treatment options
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Keratoconus
3. Competitive Intelligence Analysis for Keratoconus
4. Keratoconus: Market Overview at a Glance
4.1. Keratoconus Total Market Share (%) Distribution in 2017
4.2. Keratoconus Total Market Share (%) Distribution in 2030
5. Keratoconus: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Keratoconus Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Keratoconus Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Keratoconus Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Keratoconus Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Keratoconus Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Keratoconus Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Keratoconus Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Keratoconus Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Keratoconus Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Keratoconus Treatment and Management
8.2. Keratoconus Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Keratoconus Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Keratoconus: Seven Major Market Analysis
13.1. Key Findings
13.2. Keratoconus Market Size in 7MM
13.3. Keratoconus Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Keratoconus Total Market Size in the United States
15.1.2. Keratoconus Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Keratoconus Total Market Size in Germany
15.3.2. Keratoconus Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Keratoconus Total Market Size in France
15.4.2. Keratoconus Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Keratoconus Total Market Size in Italy
15.5.2. Keratoconus Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Keratoconus Total Market Size in Spain
15.6.2. Keratoconus Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Keratoconus Total Market Size in the United Kingdom
15.7.2. Keratoconus Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Keratoconus Total Market Size in Japan
15.8.3. Keratoconus Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Keratoconus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/